Overview: CEBPA Mutation TestIntroduction: The CEBPA Mutation Test detects CEBPA gene mutations linked to acute myeloid leukemia, causing fatigue or frequent infections. Aligned with 2023 ASH guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected leukemia.
Other Names: CEBPA Gene Assay, AML Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CEBPA mutation testing began in the 2000s with AML research. PCR-based assays emerged in the 2010s, improving diagnostic accuracy for leukemia.
Purpose: Diagnoses acute myeloid leukemia, guides treatment, and monitors CEBPA mutations in patients with fatigue or frequent infections.
Test Parameters: 1. CEBPA Mutation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report symptoms like fatigue or infections, and list medications like chemotherapy.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, frequent infections, or family history of leukemia. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for leukemia treatment.
Procedural Considerations: Uses PCR to detect CEBPA mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low sample quality or improper storage can reduce sensitivity. Contamination may cause false positives.
Clinical Significance: Positive CEBPA mutations confirm AML, prompting chemotherapy or transplant. Negative results suggest alternative diagnoses.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: Bone marrow biopsy, cytogenetic testing, or FLT3 mutation test to confirm AML or assess disease extent.
Test Limitations: False negatives may occur with low mutation levels. Results require clinical correlation with pathology.
References: ASH AML Guidelines, 2023; Blood, Döhner H, 2022.
